Please login to the form below

Not currently logged in
Email:
Password:

Fresenius Kabi recalls anastrozole tablets

Fresenius Kabi has commenced a voluntary recall of two batches of anastrozole tablets shipped to the US, after indications of contamination

Fresenius Kabi has commenced a voluntary recall of two batches of 1mg dosage breast cancer drug anastrozole tablets shipped to the US, after indications of cross contamination – the company having found other medicines in some of the bottles containing anastrozole tablets.

The German drug maker is recalling 7,192 bottles, each bottle containing 30 x 1mg tablets, which expire in May 2011. Around 105 million anastrozole tablets are sold annually in the US.

Launched just three months ago, anastrozole tablets are manufactured at Fresensius Kabi Oncology's plant in Baddi (Himachal Pradesh, India). The tablets are sold in the US through Fresenius Kabi's local unit, APP Pharmaceuticals.

An analyst with brockerage firm Sharekhan, Sapna Jhawar, estimates a moderate financial impact since the market is big and there are limited players in the oncology space. It is anticipated, however, that competitors will fill the gap left by the recall and that Fresenius will find it difficult to regain the market quickly.

The total size of the market for the medicine was said to be $917m in 2009 in the US with the medicine originally made by AstraZeneca and sold under the brand name of Arimidex.

Fresenius Kabi acquired the Delhi-based cancer drug maker by buying out the Indian promoters shares two years ago. Shortly after, they acquired APP Pharmaceuticals.

Although product recalls are common globally, such developments related to Indian drug makers have come under the spotlight, especially after 30 drugs made by the country's largest drug maker Ranbaxy at its two Indian plants have been banned for manufacturing lapses. Sun Pharma has also received two warning letters for manufacturing lapses at two of its overseas plants.

4th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics